A Phase 1 interventional study of BCD-261, dose 1 and BCD-261, dose 2 in Healthy, sponsored by Biocad. Recruiting at 1 site in Russian Federation. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-16.
Sponsored by Biocad · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Colitis, Ulcerative with a site in Russian Federation — 2 open to participants now, 2 under way, none of them phase 3. Colitis, Ulcerative · Russian Federation.
Among the 73 studies in Colitis, Ulcerative with a site in Russian Federation, this one is the 65th largest by planned enrollment of the 70 interventional ones that give a count, is the only one that started in 2024, is the only one in phase 1, and was the 73rd registered.
1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →2 of the 73 studies in Colitis, Ulcerative with a site in Russian Federation are open now. Recruiting first, the newest first:
Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department · Sites in Russian Federation
Ages 18+
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 45 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 36 · Phase 3 33 · Phase 4 2
First in 2005; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 70 across 1,238 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 284 across the 70 interventional studies, 1,731 across the 3 observational. Of the 68 that completed or were terminated, 55 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 73 have an industry lead sponsor. The 10 most frequent:
Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.
Biocad has 2 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 73 studies in Colitis, Ulcerative with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of BCD-261 after single subcutaneous injection at ascending doses and proposed therapeutic doses to healthy male subjects aged from 18 to 45 years old.
The study consists of the first stage (dose escalation) and the second stage (dose expansion).
The study is conducted in 2 stages. During the Stage 1 of the study, dose escalation is performed in several cohorts to assess the effects of dose-limiting toxicity (DLT), the maximum tolerated dose of BCD-261.
During the dose escalation one subject ("sentinel volunteer") will be included in cohort 1. Starting from the 2nd cohort and up to the 6th cohort, the study is planned within a classic "3+3" design.
Based on the results of the analysis of the Stage 1 data, including the assessment of safety, pharmacodynamics, pharmacokinetics, immunogenicity of BCD-261, a decision will be made on the possibility of switching to the Stage 2 of the study (dose expansion).
DLT events will be monitored for 7 days after BCD-261 injection (during Stage 1), and may include any of CTCAE 5.0 grade ≥3 adverse events that are at least possibly related to the study drug.
During the Stage 2 an extended study of the safety, pharmacodynamics, pharmacokinetics, and immunogenicity of BCD-261 at two pre-selected proposed therapeutic doses, is carried out with the inclusion of several additional cohorts of healthy caucasians and asians.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Administration and use of the following drugs:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in Cohort 1 will receive BCD-261 at a dose 1 during the Stage 1. Depending on the DLT, the cohort may include 1 to 3 subjects.
Drug: BCD-261, dose 1
Subjects in Cohort 2 will receive BCD-261 at a dose 2 during the Stage 1. Depending on the DLT, the cohort may include 3 to 6 subjects.
Drug: BCD-261, dose 2
Subjects in Cohort 3 will receive BCD-261 at a dose 3 during the Stage 1. Depending on the DLT, the cohort may include 3 to 6 subjects.
Drug: BCD-261, dose 3
Subjects in Cohort 4 will receive BCD-261 at a dose 4 during the Stage 1. Depending on the DLT, the cohort may include 3 to 6 subjects.
Drug: BCD-261, dose 4
Subjects in Cohort 5 will receive BCD-261 at a dose 5 during the Stage 1. Depending on the DLT, the cohort may include 3 to 6 subjects.
Drug: BCD-261, dose 5
Subjects in Cohort 6 will receive BCD-261 at a dose 6 during the Stage 1. Depending on the DLT, the cohort may include 3 to 6 subjects.
Drug: BCD-261, dose 6
Subjects in Cohort 7 will receive BCD-261 at a pre-specified proposed therapeautic dose X during the Stage 2. DLT events will not be assesed during the Stage 2. Cohort 7 will enroll 6 caucasian healthy subjects, who will recieve single subcutaneous injection of BCD-261 solution in vials.
Drug: BCD-261, pre-specified therapeautic dose X
Subjects in Cohort 8 will receive BCD-261 at a pre-specified proposed therapeautic dose X during the Stage 2. DLT events will not be assesed during the Stage 2. Cohort 8 will enroll 6 caucasian healthy subjects, who will recieve single subcutaneous injection of BCD-261 solution in pre-filled syringes.
Drug: BCD-261, pre-specified therapeautic dose X
Subjects in Cohort 9 will receive BCD-261 at a pre-specified proposed therapeautic dose X during the Stage 2. DLT events will not be assesed during the Stage 2. Cohort 9 will enroll about 10 asian healthy subjects, who will recieve single subcutaneous injection of BCD-261 solution in pre-filled syringes.
Drug: BCD-261, pre-specified therapeautic dose X
Subjects in Cohort 10 will receive BCD-261 at a pre-specified proposed therapeautic dose Y during the Stage 2. DLT events will not be assesed during the Stage 2. Cohort 10 will enroll about 10 asian healthy subjects, who will recieve single subcutaneous injection of BCD-261 solution in pre-filled syringes.
Drug: BCD-261, pre-specified therapeautic dose Y
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Also known as: anti-TL1A
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Also known as: anti-TL1A
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Also known as: anti-TL1A
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Also known as: anti-TL1A
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Also known as: anti-TL1A
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Also known as: anti-TL1A
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
Also known as: anti-TL1A
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
Also known as: anti-TL1A
Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
Also known as: anti-TL1A
Proportion of subjects with adverse reactions
Time frame: 127 days
Proportion of subjects with serious adverse reactions
Time frame: 127 days
Proportion of subjects with CTCAE 5.0 grade 3 or higher adverse reactions
Time frame: 127 days
Proportion of subjects who prematurely withdrew from the study due to adverse reactions
Time frame: 127 days
Cmax (Maximum concentration)
Time frame: 127 days
Tmax (Time of maximum observed concentration)
Time frame: 127 days
T1/2 (Elimination half-life period)
Time frame: 127 days
Kel (Elimination rate constant)
Time frame: 127 days
Cl (Clearance)
Time frame: 127 days
Vd (Volume of distribution)
Time frame: 127 days
Cmin (Minimum observed concentration)
Time frame: 127 days
AUC(0-1344) (Area under curve from 0 to 1344 hours)
Time frame: 57 days
AUC(0-inf) (Area under curve from 0 to infinity)
Time frame: 127 days
Plan to share: No
Started Mar 2024 (actual). Primary completion is estimated for Feb 2025, 11 months after the start.
Of 58 industry-sponsored phase 1 interventional studies under Colitis, Ulcerative, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's planned 11 months is close to that.
Counting every sponsor, half of 84 studies reached it within 13 months; a quarter within 8 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.